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Pulmonary infection is the cause of the majority of exacerbations of CE Despite 
international guidelines, optimal antibiotic regime to treat acute exacerbations is not 
fully defined, and clinical practice frequently differs between centres. The primary 
clinical question of this systematic review was: How effective is antibiotic therapy 
ha the management of CF? Methods:  A search of medical iterature databases from 
1966 to March 2C03 was undertaken for RCI"s or meta analyses of antibiotic 
therapy ha CF, including randomised, double blind, controlled trials (determined 
independently by 2 reviewers) of antibiotic vs placebo/antibiotic) which reported 
>3 days of cl inical outcomes. Where data were available and appropriate to pool, 
trials were combined using RevMan 4.2.3. Results:  27 RCTs and 10 systematic 
reviews were analysed. Limited pooling of studies was feasible due to diverse 
nature of study populations and outcomes measures. Do antibiotics work in acute 
exacerbations? 2 placebo controlled trials performed in exacerbations of CF have 
demonstrated improvement in cl inical state. Which antibiotics work in acute 
exacerbations? Specific antibiotic choice is diverse. There is no convincing 
evidence that single antipseudomonal antibiotic is more effective than combination 
antibiotics. Do maintenance antibiotics work? Studies have examined the use of 
antibiotics in stable patients with CF.A small  lung function benefit was observed in 
patients receiving anti staphylococcal maintenance therapy. Short term use of 
macrolides mad nebulised aminoglycosides are effective in stable patients. 
Conclusions: There are l imited RCI's to support specific antibiotic hoice in CF. 
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The aim of this study was to evaluate the in vitro efficacy of levofloxacin (lvx), a 
recently commercial ized quinolone with activity against Gram positive and Gram 
neg bacterial strains. In particular we  assessed the activity of lvx against non 
fermentat ive Gram neg strains (l~aeruginosa (Pc), A.~ylosoxidans (A~9, 
S.maltophiIio (Sin), B.cepacio complex (Bc)) from CF patients. 
Methods:  From Jan. 2003 to July 2CO4 we isolated 524 non fermentative Gram neg 
strains at the Tuscan Regional CF Center, of which 434 (82.8%) were Pa, 35 (6.6%) 
were Ax; 28 (5.3%) were Srrg and 27 (5.1%) were Bc. Al l  of these were tested 
against lvx. 
Results: 209 out of 434 (48.15%) of Pa isolates were susceptible to lvx, whi le  30 
(6.9%) had intermediate susceptibility and 195 (44.9%) were resistant. N ine  out of 
35 (25.7%) isolates of A.x were susceptible, 3 (8.5%) were intermediate susceptible 
and 23 (65.7%) were resistant to lvx. 18 out of 28 (64.2%) of Sm were ms~eptible 
whi le  5 (17.8%) were intermediate susceptible mad 5 (17.8%) were resistant. Seven 
out of 27 isolates (25.9%) of Bc were susceptible whi le  5 (18.5%) were intermediate 
sensitive mad 15 (55.5%) were resistant. 
Conclusions: The quinolones are a class of antimicrobial agents which are 
particularly interesting for CF because of their spectrum of activity and the 
possibility of oral administration. Hal f  of the Pa isolates from our Center were 
susceptible to lvx notwithstanding the fact that our patients had been treated 
previously with other quinolones. In regard to the other non fermentative Gram neg 
strains, we  found that lvx had notable activity against Srr~ 
Our data indicate that lvx has good activity against non fermentative Gram neg 
isolates from CF patients and seems, therefore, to have potential for these types of 
patients. 
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Totally inaplantable vascular access devices (TIVAD) have facilitated repetitive venous 
access for antibiotic (AS) treatment as well the quality of life of CF patients. May 
continuous compared to intemaittent LV. AS treatment fllrough TIVAD promote 
complications such as occlusion, infection of the catheter and local vascula fllrombosis. 
We retrospectively reviewed the complications that have occuned with TIVAD in the 
cohort of adult CF patients followed at the Unive~ sity Hospital of Lausanne (CHUV), 
between 1995 and 2004. We collected the total number of AS courses (continuous vs 
discontinuous) and the type of antibiotics. 
Out of the 24 CF patients, 13 (56%) had a TIVAD. Mean duration of TIVAD was 32 
months per device (7 to 101 months). Out of tim 19 implanted TIVAD, 12 had at least 
i complication (range: 1 3) (Table 1). Despite the same amount of total IYL AS cotu ses, 
continuous IYL treatments (that always consisted in ceftazidinae or cefepinae) were 
significantly associated to an inc~ ease risk of TIVAD complications qJ 001) (Table 2). 
Table 1 
No Cutaneous Local 
Total **flux Infection Occlusion Ruptui e N ct c~ls tla ombc~is 
n (%) 18 (100) 9 (50) 4 (23) 2 (12) 1 (5) 1 (5) 1 (5) 
Table 2 
No of 7LKVD duration Total no of IV  No continous 
TIAVD (months)* coui ses*/TIVAD IV  couises*fTIVAD 
No Complicatiotts 7? 26 ! 1 
Complicatiotts 35 9 5 4 
p value 049 026 001 
*n~mberg cz~ medtcz~g 
We found that the use of continuous IYL treatment was associated with an increase risk 
of TIVAD complication. Whether the type of antibiotic, the speed of the pump play a 
role need to be assessed. We are now Ix ospectively recording data to confirm and to try 
to explain these findings. 
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Oral antistaphylococcus therapy in CF is represented by a relatively large number 
of antibiotics, ha fact, the real efficient reatment consists of just a few antimicr obial 
agents, mainly flucloxaciIina (which has proved its efficiency ha t ime) and some 
new macrolides. Unforttmately, flucloxaciIina is not available ha Romania yet, so 
the main oral antistaphylococcus antibiotics are from the macrolides group. 
Reconsidering the ability of Iincomycin to penetrate in body tissues very well ,  we  
used this antibiotic for oral therapy in CF. Paper aim: to present cl inical 
observations regarding the treatment with Iincomycin ha CF patients. Methods: a 
group of 12 children with CF (5 females, 7 males, mean age 8,4 years) fol lowed up 
by the Timisoara CF Centre who received oral Iincomycin was analysed. 
Lincomycin was given in the periods of moderate xacerbations of infection for a 
longer period (up to 21 days) at a dose of 30 mg/kg body/day, 3 times a day. 
Lincomycin was introduced in the fo l lowing cases: macrolides resistance, 
gastrointestinal intolerance, persistent positive culture from sputum. Results: in 4 
patients (33,3%, mean age 9,25 years) infection was eradicated; in 5 patients 
(41,6%, mean age 7,8 years) the periods of exacerbations were rarer and milder. In 
3 patients (25%, mean age 8,3 years) only a slightly amelioration of symptoms for 
the period of Iincomycin administration was observed, but no negative sputum 
culture was noticed. We did not notice may StaphyloccocaI strains resistance on the 
period of treatment. Conclusions: l~ncomycin an be an alternative treatment for oral 
antist aphilococcus therapy in CF mad because it is not a beta lactam antibiotic, it can 
be efficient for the treatment of MRSA infection as well. 
